|
WO2021075559A1
|
|
Cell growth inhibitor or cell death inducer for cancer-associated fibroblasts
|
|
WO2021039932A1
|
|
Method for diagnosing relapsing-remitting multiple sclerosis, secondary-progressive multiple sclerosis, atypical multiple sclerosis, and neuromyelitis optica-related disease, and diagnostic biomarker
|
|
WO2021010369A1
|
|
Method for detecting circulating tumor cells using virus
|
|
WO2020241660A1
|
|
Preventive or therapeutic agent for diabetic retinopathy
|
|
WO2020204086A1
|
|
DUAL ANTIGEN-RECOGNIZING iPS CELL-DERIVED CHIMERA ANTIGEN RECEPTOR-EXPRESSING T-CELL THERAPEUTIC METHOD
|
|
WO2020179902A1
|
|
Malaria parasite growth inhibitor
|
|
WO2020175689A1
|
|
Antibody capable of binding to truncated mutant calreticulin, and diagnostic, prophylactic or therapeutic drug for myeloproliferative neoplasms
|
|
WO2020149258A1
|
|
Immune checkpoint inhibitor
|
|
US2020318064A1
|
|
Agent for accelerating maturation or aging of cells
|
|
WO2019203168A1
|
|
Diagnosis of myeloproliferative neoplasm
|
|
WO2019082940A1
|
|
Ryanodine receptor inhibitor
|
|
WO2019009328A1
|
|
Iron nutritional status improving agent
|
|
WO2018151285A1
|
|
Prophylactic or therapeutic drug for itching skin diseases
|
|
WO2018235247A1
|
|
Anti-cd10 antibody
|
|
WO2017154897A1
|
|
METHOD FOR DETECTING slow-VISA
|
|
WO2017146035A1
|
|
Method for producing inner ear cells
|
|
EP3369811A1
|
|
Method for producing pancreatic endocrine cells, and transdifferentiation agent
|
|
WO2017007031A1
|
|
Method for evaluating lymph node metastatic potential of endometrial cancer
|
|
US2017333516A1
|
|
Preventive or therapeutic agent for age-related macular degeneration
|
|
US2017211046A1
|
|
Pancreatic endocrine cells, method for producing same, and transdifferentiation agent
|
